| Title |
Neurofibromatosis type I with breast cancer: not only for women!
|
|---|---|
| Published in |
Hereditary Cancer in Clinical Practice, February 2014
|
| DOI | 10.1186/1897-4287-12-5 |
| Pubmed ID | |
| Authors |
Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Anil N Kumar, Samit Purohit, Belathur Kalegowda Viveka, Kamalakannan Rahul Rajan, Mohammed Abdul Lateef Zameer, Prabhu Namitha, Monika Lamba Saini, Hatem A Azim, Kamal S Saini |
| Abstract |
The association of neurofibromatosis type I with invasive male breast cancer is a rare clinical entity with only one case in literature reported in 1953. Women with NF1 are at risk of developing breast cancer and men also may be at risk but there is scarce data on the risk and association of NF1 with male breast cancer due to its rarity. Established clinical trials in male breast cancer patients are lacking and the results are extrapolated from female breast cancer patients. The treatment of male breast cancer is followed as per the guidelines of premenopausal female breast cancer and tamoxifen is the hormone treatment in them. Mendes et al suggests that silencing of NF1 gene confers resistance to tamoxifen. Our conclusions are that since NF1 is mutated or deleted in one third of sporadic breast cancers, its role as a molecular driver for treatment has to be further explored. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 13% |
| Student > Postgraduate | 2 | 13% |
| Researcher | 2 | 13% |
| Student > Ph. D. Student | 2 | 13% |
| Unspecified | 1 | 6% |
| Other | 2 | 13% |
| Unknown | 5 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 50% |
| Unspecified | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Unknown | 5 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2014.
All research outputs
#20,655,488
of 25,373,627 outputs
Outputs from Hereditary Cancer in Clinical Practice
#173
of 260 outputs
Outputs of similar age
#175,626
of 237,559 outputs
Outputs of similar age from Hereditary Cancer in Clinical Practice
#4
of 7 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 260 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,559 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.